SBRA Stock - Sabra Health Care REIT, Inc.
Unlock GoAI Insights for SBRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $703.24M | $647.51M | $624.81M | $569.54M | $598.57M |
| Gross Profit | $476.15M | $452.27M | $462.20M | $428.34M | $467.02M |
| Gross Margin | 67.7% | 69.8% | 74.0% | 75.2% | 78.0% |
| Operating Income | $257.03M | $221.71M | $234.84M | $210.75M | N/A |
| Net Income | $126.71M | $13.76M | $-77,605,000 | $-113,256,000 | $138.42M |
| Net Margin | 18.0% | 2.1% | -12.4% | -19.9% | 23.1% |
| EPS | $0.54 | $0.06 | $-0.34 | $-0.52 | $0.67 |
As of March 31, 2022, Sabra's investment portfolio included 416 real estate properties held for investment. This consists of (i) 279 Skilled Nursing/Transitional Care facilities, (ii) 59 Senior Housing communities (Senior Housing - Leased), (iii) 50 Senior Housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 13 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a sales-type lease, 16 investments in loans receivable (consisting of (i) two mortgage loans, (ii) one construction loan and (iii) 13 other loans), seven preferred equity investments and one investment in an unconsolidated joint venture. As of March 31, 2022, Sabra's real estate properties held for investment included 41,445 beds/units, spread across the United States and Canada.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | UBS | Initiation | Neutral | $20 |
| October 1st 2025 | Cantor Fitzgerald | Initiation | Neutral | $20 |
| January 17th 2025 | Truist | Downgrade | Hold | - |
| January 7th 2025 | JMP Securities | Upgrade | Mkt Outperform | $20 |
| December 5th 2024 | Mizuho | Downgrade | Neutral | $20 |
| October 1st 2024 | Wells Fargo | Upgrade | Overweight | $20← $16 |
| September 13th 2024 | Citigroup | Upgrade | Buy | $20← $17 |
| January 30th 2024 | Deutsche Bank | Initiation | Buy | $21 |
| October 17th 2023 | BMO Capital Markets | Downgrade | Market Perform | $16 |
| October 16th 2023 | Wells Fargo | Upgrade | Equal Weight | $15← $13 |
| October 10th 2023 | BofA Securities | Upgrade | Buy | $16← $14 |
| October 3rd 2023 | Wedbush | Initiation | Outperform | $16 |
| September 20th 2023 | Jefferies | Upgrade | Buy | $15← $11 |
| August 11th 2023 | BofA Securities | Upgrade | Neutral | $14← $11 |
| July 27th 2023 | Berenberg | Initiation | Hold | $13 |
Earnings History & Surprises
SBRAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $0.38 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.38 | $0.38 | 0.0% | = MET |
Q3 2025 | Aug 4, 2025 | $0.37 | $0.38 | +2.7% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $0.36 | $0.37 | +2.8% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $0.36 | $0.36 | 0.0% | = MET |
Q4 2024 | Oct 31, 2024 | $0.36 | $0.37 | +2.8% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.35 | $0.36 | +2.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.34 | $0.35 | +2.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.34 | $0.33 | -2.9% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $0.34 | $0.34 | 0.0% | = MET |
Q3 2023 | Aug 7, 2023 | $0.34 | $0.34 | 0.0% | = MET |
Q2 2023 | May 3, 2023 | $0.34 | $0.34 | 0.0% | = MET |
Q1 2023 | Feb 21, 2023 | $0.36 | $0.37 | +2.8% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.38 | $0.36 | -5.3% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.37 | $0.39 | +5.4% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.38 | $0.39 | +2.6% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $0.36 | $0.37 | +2.8% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.38 | $0.38 | 0.0% | = MET |
Q3 2021 | Aug 4, 2021 | $0.38 | $0.39 | +2.6% | ✓ BEAT |
Latest News
Sabra Health Care REIT Narrows FY2025 FFO Guidance from $1.45-$1.47 to $1.46-$1.47 vs $1.47 Est
➖ NeutralSabra Health Care REIT Q3 FFO $0.36 Misses $0.37 Estimate, Sales $190.037M Beat $187.279M Estimate
➖ NeutralWells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $20
➖ NeutralCantor Fitzgerald Initiates Coverage On Sabra Health Care REIT with Neutral Rating, Announces Price Target of $20
➖ NeutralTruist Securities Maintains Hold on Sabra Health Care REIT, Raises Price Target to $20
📈 PositiveWells Fargo Maintains Overweight on Sabra Health Care REIT, Raises Price Target to $21
📈 PositiveBMO Capital Maintains Market Perform on Sabra Health Care REIT, Raises Price Target to $22
📈 PositiveFrequently Asked Questions about SBRA
What is SBRA's current stock price?
What is the analyst price target for SBRA?
What sector is Sabra Health Care REIT, Inc. in?
What is SBRA's market cap?
Does SBRA pay dividends?
Similar Stocks
Real Estate SectorExplore stocks similar to SBRA for comparison